Terms: = Prostate cancer AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Clinical Outcome
6 results:
1. The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer.
Richardsen E; Ness N; Melbø-Jørgensen C; Johannesen C; Grindstad T; Nordbakken C; Al-Saad S; Andersen S; Dønnem T; Nordby Y; Bremnes RM; Busund LT
Am J Pathol; 2015 Oct; 185(10):2722-30. PubMed ID: 26272362
[TBL] [Abstract] [Full Text] [Related]
2. Tumor infiltrating B-cells are increased in prostate cancer tissue.
Woo JR; Liss MA; Muldong MT; Palazzi K; Strasner A; Ammirante M; Varki N; Shabaik A; Howell S; Kane CJ; Karin M; Jamieson CA
J Transl Med; 2014 Jan; 12():30. PubMed ID: 24475900
[TBL] [Abstract] [Full Text] [Related]
3. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer.
Flammiger A; Bayer F; Cirugeda-Kühnert A; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
APMIS; 2012 Nov; 120(11):901-8. PubMed ID: 23009114
[TBL] [Abstract] [Full Text] [Related]
4. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.
Zlobec I; Lugli A
World J Gastroenterol; 2009 Dec; 15(47):5898-906. PubMed ID: 20014453
[TBL] [Abstract] [Full Text] [Related]
5. Biomarker discovery in urogenital cancer.
Said J
Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
[TBL] [Abstract] [Full Text] [Related]
6. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer.
D'Amico AV; Hanks GE
Cancer; 1993 Nov; 72(9):2638-43. PubMed ID: 7691393
[TBL] [Abstract] [Full Text] [Related]
